SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Journal of Attention Disorders
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Right arrow Citation Map
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via HighWire
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Tenenbaum, S.
Right arrow Articles by Green, L.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Tenenbaum, S.
Right arrow Articles by Green, L.
Social Bookmarking
 Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

An experimental comparison of Pycnogenol® and methylphenidate in adults with Attention-Deficit/ Hyperactivity Disorder (ADHD)

S. Tenenbaum

J.C. Paull

E.P. Sparrow

D.K. Dodd

L. Green

Twenty-four adults (24 to 53 years old) with Attention-Deficit/Hyperactivity Disorder (ADHD), Combined Type, were studied in a double-blind, placebo-controlled, crossover study of Pycnogenol® and methylphenidate. Pycnogenol is an antioxidant derived from the bark of the French maritime pine tree. Methylphenidate is a standard pharmaceutical intervention for ADHD. Anecdotal reports suggest that Pycnogenol improves concentration in adults with ADHD without adverse side effects.

Participants received Pycnogenol, methylphenidate, and placebo, each for 3 weeks, in a randomized and counterbalanced order. Although ADHD symptoms improved during treatment, neither methylphenidate nor Pycnogenol outperformed the placebo control, as measured by self-report rating scales, rating scales completed by the individual's significant other, and a computerized continuous performance test. The conservative dosage levels and relatively brief length of treatment may have contributed to the absence of significant differences among treatment conditions. Implications for future research are noted.

Journal of Attention Disorders, Vol. 6, No. 2, 49-60 (2002)
DOI: 10.1177/108705470200600201


Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?


This article has been cited by other articles:


Home page
J PsychopharmacolHome page
M Koesters, T Becker, R Kilian, J. Fegert, and S Weinmann
Limits of meta-analysis: methylphenidate in the treatment of adult attention-deficit hyperactivity disorder
J Psychopharmacol, September 1, 2009; 23(7): 733 - 744.
[Abstract] [PDF]


Home page
J PsychopharmacolHome page
J Godfrey
Safety of therapeutic methylphenidate in adults: a systematic review of the evidence
J Psychopharmacol, March 1, 2009; 23(2): 194 - 205.
[Abstract] [PDF]



Advertisement